WO2004091635A1 - 子宮内膜症及び婦人科疾患の治療薬 - Google Patents
子宮内膜症及び婦人科疾患の治療薬 Download PDFInfo
- Publication number
- WO2004091635A1 WO2004091635A1 PCT/JP2004/005326 JP2004005326W WO2004091635A1 WO 2004091635 A1 WO2004091635 A1 WO 2004091635A1 JP 2004005326 W JP2004005326 W JP 2004005326W WO 2004091635 A1 WO2004091635 A1 WO 2004091635A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lactic acid
- points
- endometriosis
- cyclic
- poly
- Prior art date
Links
- 208000016908 Female Genital disease Diseases 0.000 title claims abstract description 7
- 201000009273 Endometriosis Diseases 0.000 title description 30
- 229920001432 poly(L-lactide) Polymers 0.000 claims abstract description 27
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 19
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims abstract description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910001873 dinitrogen Inorganic materials 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 52
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 41
- 201000010099 disease Diseases 0.000 claims description 26
- 230000005494 condensation Effects 0.000 claims description 17
- 238000009833 condensation Methods 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 28
- 230000002829 reductive effect Effects 0.000 abstract description 5
- 238000010438 heat treatment Methods 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 description 36
- 229940124597 therapeutic agent Drugs 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 13
- 208000035475 disorder Diseases 0.000 description 13
- 208000005171 Dysmenorrhea Diseases 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 10
- 208000002296 eclampsia Diseases 0.000 description 8
- 231100000957 no side effect Toxicity 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000005906 menstruation Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 208000008035 Back Pain Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 206010036772 Proctalgia Diseases 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 229940126585 therapeutic drug Drugs 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 206010016326 Feeling cold Diseases 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 3
- 229960000766 danazol Drugs 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010000084 Abdominal pain lower Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000017657 Menopausal disease Diseases 0.000 description 2
- 206010053156 Musculoskeletal discomfort Diseases 0.000 description 2
- 208000000450 Pelvic Pain Diseases 0.000 description 2
- 206010064229 Pelvic discomfort Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 239000001527 calcium lactate Substances 0.000 description 2
- 229960002401 calcium lactate Drugs 0.000 description 2
- 235000011086 calcium lactate Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000000235 effect on cancer Effects 0.000 description 2
- 206010014665 endocarditis Diseases 0.000 description 2
- 210000005168 endometrial cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- KVZLHPXEUGJPAH-DKWTVANSSA-N 2-hydroxypropanoic acid;(2s)-2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.C[C@H](O)C(O)=O KVZLHPXEUGJPAH-DKWTVANSSA-N 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006312 Breast swelling Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000002013 dioxins Chemical class 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 231100000507 endocrine disrupting Toxicity 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 201000009274 endometriosis of uterus Diseases 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 231100000551 menstrual abnormality Toxicity 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000026843 stiff neck Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Definitions
- the present invention relates to a therapeutic agent for gynecologic diseases suitable for gynecological disorders such as eclampsia, and in particular to a therapeutic agent for gynecological diseases with few side effects when taken.
- Endometriosis is thought to occur because menstrual blood regurgitation etc. cause endometrial cells to occur in places other than eclampsia. External endometriosis is likely to cause hemorrhage and adhesion of cells in the pelvic cavity, resulting in poor blood circulation, resulting in various symptoms such as pain, menopausal symptoms, constipation and stiff shoulders. Ru.
- Intrinsic factor deletion of artificial chemical detoxification enzyme gene, deletion of tumor suppressor gene
- Endometriosis is a disease that is very difficult to cure, and treatments include surgery and medication.
- patients who wish to become pregnant may have surgery to remove only the lesions and leave the ovaries, but abnormal cells often adhere to surrounding cells and the number of patients after surgery
- Medications include: 1. pseudo-menopausal and 2. pseudo-pregnancy. Medications used in any of these treatments are designed to temporarily stop menstruation and thereby prevent or reduce endometriosis.
- G n R H antagonists examples include G n R H antagonists, danazol, medium dose pills, low dose pills and the like.
- G n R H antagonists are agents that suppress the progression of endometriosis by suppressing ovarian function.
- Danazol is a therapeutic drug that directly acts on a lesion of eclampsia.
- a pill is a drug generally used for contraceptive purposes, ovulation and the endodontic membrane It may also be used for the purpose of suppressing the progression of ectocervical intima, since it suppresses the growth of (Refer to Japanese Patent Application Laid-Open No. 10 0 3 6 3 3 (claims 1 and 2 6).
- the drugs used for either therapy have large side effects and impose a large burden on patients.
- the G 'n RH antagost creates a low estrogenic state to create a pseudo-menopausal state. Symptoms similar to menopausal disorders such as dizziness and side effects such as bone loss are seen.
- Danazol is associated with strong side effects such as liver dysfunction and thrombosis, and effects such as weight gain and changes in voice.
- Medium-dose pills have side effects such as thrombosis, nausea, headache, weight gain, and breast swelling. The low dose pills are not as serious side effects as the medium dose pills, but similar symptoms are recognized.
- the present invention was made focusing on the above-mentioned points, and an object of the present invention is to provide a therapeutic drug for gynecological diseases with few side effects.
- Another object of the present invention is to provide a remedy for ectocervical endocarditis with few side effects.
- the therapeutic agent for gynecological diseases of the present invention is obtained by dehydrating condensation of L-lactic acid by reducing pressure and raising temperature in a nitrogen gas atmosphere, cyclic and / or / or It contains a linear poly L-lactic acid mixture as an active ingredient.
- cyclic and / or linear poly L monolactic acid mixture is a compound obtained by heat condensation of L mono lactic acid
- general formula of the cyclic poly L monolactic acid compound is The general formula of the linear poly L monolactic acid compound is shown in Formula 2, respectively. Note that z in the equations 1 and 2 is the degree of condensation. [Formula 1]
- gynecological diseases women-specific diseases such as dysmenorrhea, menstrual abnormalities, eclampsia, ectopic myoma, ovarian cyst, endometriosis, breast cancer, ectopic cancer, ovarian cancer, etc., symptoms of these diseases and treatment Side effects, and also include menopausal disorders, anemia, coldness, etc. that are particularly manifested in women due to the effects of female hormones, etc.
- gynecological diseases by enhancing the body's immune system.
- a drug for treating gynecological diseases that can alleviate the symptoms of gynecological diseases.
- the gynecological diseases may be endometriosis.
- the endometrial cell thickening can be suppressed by inhibiting the energy production of the ectocervical cells that have grown outside the eclampsia, and the treatment itself has no side effects.
- An endometriosis drug is obtained.
- this therapeutic agent also has the function of regulating the immune system of the body, which alleviates accompanying symptoms such as abdominal pain and back pain.
- the therapeutic agent for gynecological diseases of the present invention is effective in cyclic and Z- or linear poly-L-lactic acid mixtures obtained by dehydration condensation of L-monolactic acid in a nitrogen gas atmosphere by stepwise depressurization and temperature elevation. It is contained as a component.
- the therapeutic agent for gynecological diseases may contain 80% by weight or more of a mixture of cyclic and Z- or linear poly-L-lactic acid as an active ingredient.
- a therapeutic agent for gynecological diseases having a high content of the active ingredient in the intake of the therapeutic agent per dose can be obtained, and a sufficient amount of the active ingredient can be ingested even with a small intake.
- the therapeutic agent for gynecological disorders is one containing a cyclic and Z- or linear poly-L-lactic acid mixture at 400 mg or more in a daily dose. It is also good.
- the daily intake of the therapeutic agent for gynecological disorders contains a sufficient amount of cyclic and / or linear poly L-lactic acid mixture, the effect on gynecological disorders is obtained. Is obtained.
- the cyclic and / or linear poly (L-L-lactic acid) mixture contained as an active ingredient of a gynecological disorder therapeutic agent has a condensation degree in the range of 3 to 19 May be
- the active ingredient for treating gynecological diseases includes a fraction having a particularly high antitumor effect among cyclic and Z or linear poly L-lactic acid mixtures. It is possible to obtain a gynecological drug with high efficacy.
- FIG. 1 is a table (No. 1) showing the results for each symptom of this drug administration test.
- FIG. 2 is a table (No. 2) showing the results for each symptom of the present therapeutic drug administration test.
- FIG. 3 is a graph showing the transition of the total score for each symptom.
- FIG. 4 is a graph showing the transition of the total score of all symptoms.
- the therapeutic agent for gynecological disorders according to the present invention can be obtained by dehydrating condensation of L-lactic acid in a nitrogen gas atmosphere by reducing pressure and raising temperature.
- it contains a linear poly-L-lactic acid mixture as an active ingredient.
- a therapeutic agent for gynecological diseases which has the effect of enhancing the immunity of the body and has no side effects is realized.
- it has the effect of suppressing the thickening of ectocervical intima cells and the effect of enhancing immunity, and is a therapeutic agent for gynecological diseases suitable for the treatment of endometriosis.
- the poly (L-lactic acid) lactic acid used as an active ingredient of a gynecological disorder therapeutic agent in the present invention has an effect on various diseases, and in particular, has a remarkable effect on various cancers. It has been confirmed as a result of biological experiments that poly L-lactic acid has an effect of promoting apoptosis of malignant cells such as cancer, an effect of acting as a regulator of various phenomena in vivo, and a remarkable sedative effect.
- Poly L-lactic acid has a remarkable effect on cancer because (1) it inhibits the energy production of cancer cells and drives it to self-destruction, (2) the medical condition improves by improving the body's immune system. It is speculated that it is due to We note that endometriosis is caused by proliferation of dysmorphic cells as well as cancer, and poly L-lactic acid has a remarkable effect on cancer. 4 005326
- cytokine is a trace chemical substance that regulates cell proliferation, division, and apoptosis, and the environment in the peritoneal cavity is getting worse.
- prostaglandins one of the causes of pain, are increased, while non-K cells, which control the body's immune system and suppress the growth of lesions, are decreasing.
- poly-L-lactic acid relieves symptoms by regulating immune function by preventing vagus or runaway of physiologically active substances such as cytokines.
- Oxygen dissociation is thought to involve 2-3 PG BPG (2 ⁇ ⁇ 3-bisphosglyceric acid), but poly-L-lactic acid promotes the addition of this substance, and it also induces the transformation of poly-L-lactic acid in red blood cells.
- Noble size of blood vessel is matched to size of red blood cell, size adjustment ability to smooth blood flow
- Poly (L-L-lactic acid) is obtained by dehydrating and condensing L- (L-lactic acid) stepwise in nitrogen gas atmosphere and dehydrating condensation, and it has cyclicity with various condensation degree depending on conditions such as heating temperature and heating time. And Z or a linear poly L monolactic acid mixture is obtained.
- the poly-L-monolactic acid mixture is obtained in a mixed state of a cyclic poly-L-monolactic acid compound and a linear poly-L-monolactic acid compound.
- the degree of condensation is not particularly limited, but it is desirable to contain a mixture of poly-L-lactic acid with a degree of condensation of 1 to 19 having a high antitumor effect, and a mixture of poly-L-lactic acid of degree of condensation of 5 to 14 is also included. It is better if you As mentioned above, endometriosis is caused by proliferation of atypical cells as well as cancer, so fractions with high degree of condensation of 15 to 19 in antitumor effect, 5 to 14 in degree of condensation Fractions are also expected to have a high effect on endometriosis.
- the cyclic and / or linear poly-L-lactic acid mixture obtained by the above-mentioned procedure may be used as it is as a therapeutic agent for oral intake.
- You may add sweeteners such as milk and trehalose, fortifying agents such as calcium lactate, flavors and preservatives.
- excipients, pinders, etc. may be added to form tablets, or may be packed into capsules.
- the dosage per one administration of the therapeutic agent for gynecological disorders according to the present invention is about 2 to 6 g, and it is desirable that the dosage per day be about 2 to 3 times. . Too much per dose, or too many doses per day, can be painful for the user to take the treatment, which is less preferable.
- the cyclic and / or linear mixture of poly (L-L-lactic acid) be contained in an amount of 4800 mg or more in a daily dose. If the daily therapeutic drug intake is too low, the effects of the gynecological disorder therapeutics may not be sufficiently obtained.
- a therapeutic agent for endometriosis and gynecological diseases can be obtained.
- Test subjects Patients with ectopic eclampsia endometriosis 10 (ages 22 to 35, average 28. 2). All of them were diagnosed with dysmenorrhea (6 persons with severe symptoms, 4 persons with moderate symptoms) without any prior surgery and have not received any particular treatment.
- FIG. 1 shows “menstrual pain”, “lower abdominal pain other than menstrual pain”, “back pain other than menstrual pain”, “pelvic pain and discomfort, hip discomfort”, “anal pain ⁇ push up at the time of sitting”
- the results of evaluation of the symptoms of “intercourse pain” and “overweight / overlong menstruation” are shown in FIG. 2 for “lever-like 'membranous clot”,' corruption bleeding ',' anemia, dizziness', 'fever',
- the evaluation results of “nausea, vomiting”, “stiff shoulder, head weight, headache” and “chilliness (especially in the lower extremities)” are shown.
- FIG. 3 The graph showing the transition of the total score for each symptom in the administration test results is shown in Fig. 3 and the graph showing the transition of the total score of all symptoms is shown in Fig. 4c .
- the longer the administration period for any symptom the more the symptom tends to be reduced to disappear, and it can be seen that the graph is in the lower right shoulder.
- the total score decreases as the administration period becomes longer, and the overall improvement is achieved.
- Figures 1 to 4 are numerical values of the subject's own thoughts, The clinical findings also show improvement results.
- changes in post-trial changes also showed a tendency for improvement in parallel to the symptoms after changes in the condition of the capsule fossa by internal examination and the condition of the focus area by image diagnosis. For various other symptoms, some degree of relief or disappearance was observed after the trial. In addition, after administration of this drug, no side effects such as those of conventional drugs were observed, and no abnormal values were observed in clinical laboratory data.
- this drug has two reasons: (1) it inhibits the energy production of cancer cells and drives them to self-destruction; (2) it improves the medical condition by improving the body's immune system; It is presumed to be effective against endometriosis and gynecological diseases. However, visible “improvement of immunity” does not occur in a short period, and ectocarditis itself is also time-consuming to cure, and drug administration and observation are carried out for a long period of time. It is presumed that a clear effect can be found by this.
- the therapeutic agent for gynecological diseases can alleviate general gynecological diseases and various symptoms thereof by enhancing the immunity of the body. In addition, since it has no side effects like common therapeutic agents, it can be used freely even in mild cases.
- the therapeutic agent for endometriosis according to the present invention can suppress thickening of the intimal cell of the eclampsia by inhibiting the energy production of the intimal cell of the ectopically grown in other places than the uterus.
- the body's immune system by adjusting the body's immune system, accompanying symptoms such as abdominal pain and back pain are alleviated and there are no side effects.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003-109507 | 2003-04-14 | ||
| JP2003109507A JP2004175783A (ja) | 2003-04-14 | 2003-04-14 | 子宮内膜症及び婦人科疾患の治療薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2004091635A1 true WO2004091635A1 (ja) | 2004-10-28 |
Family
ID=32709287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2004/005326 WO2004091635A1 (ja) | 2003-04-14 | 2004-04-14 | 子宮内膜症及び婦人科疾患の治療薬 |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP2004175783A (enrdf_load_stackoverflow) |
| KR (1) | KR20060002708A (enrdf_load_stackoverflow) |
| WO (1) | WO2004091635A1 (enrdf_load_stackoverflow) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102037448B1 (ko) | 2017-11-21 | 2019-10-28 | 경희대학교 산학협력단 | 데하이드로코스투스 락톤을 포함하는 자궁세포 이상증식 질환의 예방, 개선 또는 치료용 조성물 |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05310581A (ja) * | 1992-05-15 | 1993-11-22 | Koken Kk | 人を含む動物の悪性腫瘍細胞増殖抑制剤 |
| JPH06336427A (ja) * | 1993-05-26 | 1994-12-06 | Global Art Kk | 人を含む動物の悪性腫瘍細胞増殖抑制剤 |
| JPH09227388A (ja) * | 1996-02-15 | 1997-09-02 | Naganushi Tetsuaki | 大腸癌、食道癌及び乳癌より選ばれた癌に用いる抗悪性腫瘍剤 |
| JPH10130153A (ja) * | 1996-10-28 | 1998-05-19 | Shiyumeidou:Kk | 大腸癌、食道癌及び乳癌より選ばれた癌に用いる 抗悪性腫瘍剤 |
| JP2001139476A (ja) * | 1999-11-15 | 2001-05-22 | Youichirou Naganushi | 癌を含めた悪性新生物に用いる抗悪性腫瘍剤 |
| WO2001054705A1 (fr) * | 2000-01-26 | 2001-08-02 | Amato Pharmaceutical Products, Ltd. | Inhibiteurs d'implantation de cellules cancereuses |
| WO2002060457A1 (fr) * | 2001-01-24 | 2002-08-08 | Amato Pharmaceutical Products,Ltd. | Agents anti-stress |
| JP2002356433A (ja) * | 2001-05-30 | 2002-12-13 | Tendou Seiyaku Kk | 免疫賦活剤 |
| WO2003007937A1 (fr) * | 2001-07-18 | 2003-01-30 | Amato Pharmaceutical Products, Ltd. | Agent antitumoral contenant de l'acide polylactique cyclique |
| WO2003039560A1 (fr) * | 2001-11-06 | 2003-05-15 | Amato Pharmaceutical Products, Ltd. | Agent antitumoral contenant un melange d'oligomeres d'acide lactique |
| JP2004155670A (ja) * | 2002-11-01 | 2004-06-03 | Youichirou Naganushi | 細胞賦活剤、細胞賦活剤製造方法及びその装置 |
-
2003
- 2003-04-14 JP JP2003109507A patent/JP2004175783A/ja active Pending
-
2004
- 2004-04-14 WO PCT/JP2004/005326 patent/WO2004091635A1/ja active Application Filing
- 2004-04-14 KR KR1020047016387A patent/KR20060002708A/ko not_active Withdrawn
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05310581A (ja) * | 1992-05-15 | 1993-11-22 | Koken Kk | 人を含む動物の悪性腫瘍細胞増殖抑制剤 |
| JPH06336427A (ja) * | 1993-05-26 | 1994-12-06 | Global Art Kk | 人を含む動物の悪性腫瘍細胞増殖抑制剤 |
| JPH09227388A (ja) * | 1996-02-15 | 1997-09-02 | Naganushi Tetsuaki | 大腸癌、食道癌及び乳癌より選ばれた癌に用いる抗悪性腫瘍剤 |
| JPH10130153A (ja) * | 1996-10-28 | 1998-05-19 | Shiyumeidou:Kk | 大腸癌、食道癌及び乳癌より選ばれた癌に用いる 抗悪性腫瘍剤 |
| JP2001139476A (ja) * | 1999-11-15 | 2001-05-22 | Youichirou Naganushi | 癌を含めた悪性新生物に用いる抗悪性腫瘍剤 |
| WO2001054705A1 (fr) * | 2000-01-26 | 2001-08-02 | Amato Pharmaceutical Products, Ltd. | Inhibiteurs d'implantation de cellules cancereuses |
| WO2002060457A1 (fr) * | 2001-01-24 | 2002-08-08 | Amato Pharmaceutical Products,Ltd. | Agents anti-stress |
| JP2002356433A (ja) * | 2001-05-30 | 2002-12-13 | Tendou Seiyaku Kk | 免疫賦活剤 |
| WO2003007937A1 (fr) * | 2001-07-18 | 2003-01-30 | Amato Pharmaceutical Products, Ltd. | Agent antitumoral contenant de l'acide polylactique cyclique |
| WO2003039560A1 (fr) * | 2001-11-06 | 2003-05-15 | Amato Pharmaceutical Products, Ltd. | Agent antitumoral contenant un melange d'oligomeres d'acide lactique |
| JP2004155670A (ja) * | 2002-11-01 | 2004-06-03 | Youichirou Naganushi | 細胞賦活剤、細胞賦活剤製造方法及びその装置 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004175783A (ja) | 2004-06-24 |
| KR20060002708A (ko) | 2006-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201345539A (zh) | 牛樟芝用於治療疾病的方法 | |
| CN109806382B (zh) | 一种乌鸡肽的组合物及其在制备治疗痛经药品中的应用 | |
| RU2364411C1 (ru) | Средство и способ профилактики рецидива кист яичников | |
| CN114869949B (zh) | 一种用于治疗妇女产后疾病的药物组合物及其制备方法 | |
| WO2004091635A1 (ja) | 子宮内膜症及び婦人科疾患の治療薬 | |
| CN108939093A (zh) | 一种含中药成分的胃肠造影剂及其制备方法 | |
| CN113750205A (zh) | 一种缓解和/或治疗女性生殖系统疾病的中药组合物 | |
| Ghosh | Clinical experience with some rare Nosodes | |
| RU2327462C1 (ru) | Способ лечения маточных кровотечений пубертатного периода | |
| CN113577090B (zh) | 牛蒡子苷在制备前列腺增生药物中的应用 | |
| JP3545512B2 (ja) | 生薬配合発泡錠 | |
| CN104056173A (zh) | 一种治疗孕妇妊娠期气血两亏的中药组合物 | |
| JP2014231518A (ja) | 子宮腫瘍の治療用医薬の調製のための７−ｔ−ブトキシイミノメチルカンプトテシンの使用 | |
| RU2424817C1 (ru) | Способ профилактики и лечения угрозы прерывания беременности у женщин с миомой матки согласно новому взгляду на ее этиопатогенез | |
| US20240374632A1 (en) | Apparatus and Method for Contact Free Delivery and Administration of Magnesium as a Drug | |
| TW200930377A (en) | Use of gestagens in combination with (6s)-5-methyltetrahydrofolate for therapy of endometriosis with simultaneous reduction of therapy side effects and reduction of the risk of congenital abnormalities at the onset of a pregnancy | |
| Drammeh et al. | Exploring uterine fibroids and its treatment in current scenario | |
| Kesavan et al. | COMPREHENSIVE REVIEW ON THE PHARMACOLOGICAL USE, SAFETY, AND CLINICAL EFFICACY OF MIFEPRISTONE AND MISOPROSTOL IN MEDICAL ABORTION | |
| CN106924679A (zh) | 一种治疗胃溃疡的药物 | |
| Dudwe et al. | A CASE STUDY AYURVEDIC MANAGEMENT OF ALOPECIA AREATA WSR OF INDRALUPTA | |
| CN109568529A (zh) | 一种治疗非炎性白带过多症的肚脐贴 | |
| WO2025148231A1 (zh) | 一种治疗妊娠剧吐的外用中药组合物 | |
| RU2282439C2 (ru) | Фармацевтическая композиция на основе веществ, влияющих на энергетический обмен, и способ профилактики фетоплацентарной недостаточности у беременных группы высокого риска | |
| Sreeni et al. | AYURVEDIC MANAGEMENT OF NON ACUTE CHOLELITHIASIS ASSOCIATED WITH UTERINE FIBROID-A CASE STUDY | |
| CN112294943A (zh) | 一种调节女性体质的牡蛎肽片 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 1020047016387 Country of ref document: KR |
|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWP | Wipo information: published in national office |
Ref document number: 1020047016387 Country of ref document: KR |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC DATED 27-12-2005 |
|
| 122 | Ep: pct application non-entry in european phase |